期刊文献+

不同组织内YAP1、E-cadherin表达与上皮性卵巢癌患者临床病理特征间的关系分析

Analysis of the relationship between the expression of YAP1 and E-cadherin in different tissues and the clinicopathological characteristics of epithelial ovarian cancer
下载PDF
导出
摘要 目的研究不同组织内Yes相关蛋白1(YAP1)、上皮钙黏蛋白(E-cadherin)表达与上皮性卵巢癌患临床病理特征间的关系。方法回顾性分析确诊为上皮性卵巢癌并行卵巢切除术的57例患者的石蜡包埋的肿瘤组织标本,同时,收集石蜡包埋的癌旁正常卵巢组织标本,对癌组织及癌旁组织分别利用免疫组化法检测YAP1、E-cadherin表达。比较不同组织内YAP1、E-cadherin阳性检出率,不同临床病理特征上皮性卵巢癌患者YAP1、E-cadherin阳性检出率差异,对57例患者行3年院外随访,观察癌组织YAP1及E-cadherin阳性、阴性患者术后3年存活率差异。结果癌组织YAP1阳性检出53例(92.98%),癌旁组织YAP1阳性检出率7例(12.28%),癌组织E-cadherin阳性检出27例(47.37%),癌旁组织E-cadherin阳性检出2例(3.51%),癌组织YAP1及E-cadherin阳性检出率高于癌旁组织(P<0.05)。FIGO分期为Ⅲ~Ⅳ期患者癌组织YAP1阳性检出率明显增高(P<0.05);FIGO分期Ⅰ~Ⅱ期、分化程度高、淋巴结未转移患者癌组织E-cadherin阳性检出率增高(P<0.05)。57例经卵巢切除术治疗的患者3年死亡23例(40.35%),存活34例(59.65%);Kaplan-Meier生存分析显示,癌组织E-cadherin阳性检出率越高患者存活率越高(Log-Rank=4.752,P<0.05)。结论在上皮性卵巢癌中,YAP1呈高水平表达,且与临床分期有显著相关性;E-cadherin在上皮卵巢癌中表达上调,与疾病进展、转移等有关,但其表达随着临床分期、分化程度、淋巴结转移情况增加而下降,一定程度上可用来预测患者预后。 Objective To study the relationship between the expression of Yes related protein 1(YAP1)and Epithelial cadherin(E-cadherin)in different tissues and the clinicopathological characteristics of epithelial ovarian cancer.Methods A retrospective analysis was conducted on paraffin-embedded tumor tissue samples from 57 patients diagnosed with epithelial ovarian cancer who underwent oophorectomy,and the paraffin-embedded paracancer normal ovarian tissue samples were collected simultaneously.Immunohistochemical methods were used to detect the expression of YAP1 and E-cadherin in the cancer tissue and paracancer tissue,respectively.Compared the positive detection rates of YAP1 and E-cadherin in different tissues,and compared the positive detection rates of YAP1 and E-cadherin in epithelial ovarian cancer patients with different clinicopathologic characteristics.57 patients were followed up for 3 years to observe the difference of 3-year survival rate of patients with positive and negative YAP1 and E-cadherin in the cancer tissues.Results The positive detection of YAP1 in cancer tissue was 53(92.98%),the positive detection of YAP1 in adjacent tissue was 7(12.28%),and the positive detection of E-cadherin in cancer tissue was 27(47.37%).The positive detection rate of E-cadherin in paracancer tissue was 2(3.51%),and the positive detection rates of YAP1 and E-cadherin in cancer tissue was significantly higher than those in paracancer tissue(P<0.05).while the positive detection rate of YAP1 in patients with FIGO stageⅢ-Ⅳwas significantly increased(P<0.05).The positive detection rate of E-cadherin in cancer tissues of patients with FIGO stageⅠ-Ⅱ,high differentiation degree and no lymph node metastasis was significantly increased(P<0.05).The 3-year mortality was 23(40.35%)and the survival rate was 34(59.65%).Kaplan-Meier survival analysis showed that the higher the positive rate of E-cadherin in cancer tissue,the higher the survival rate(Log-Rank=4.752,P<0.05).Conclusion In epithelial ovarian cancer,YAP1 is highly expressed and significantly correlated with clinical stages.The expression of E-cadherin is up-regulated in epithelial ovarian cancer,which is related to disease progression and metastasis,however,the expression of which is negatively correlated with increasing clinical stage,differentiation degree and lymph node metastasis,which can be potencailly contributed to the prediction of the prognosis of patients.
作者 夏潇 王莹 韩灵云 韩恩善 XIA Xiao;WANG Ying;HAN Lingyun;HAN Enshan(Department of Pathology,Wuzhong People's Hospital,Wu Zhong 751100,China;Department of Gynaecology,Wuzhong People's Hospital,Wu Zhong 751100,China;Department of Pathology,General Hospital of Ningxia Medical University,Yinchuan 750004,China)
出处 《宁夏医学杂志》 CAS 2023年第8期695-698,F0003,共5页 Ningxia Medical Journal
关键词 上皮性卵巢癌 Yes相关蛋白1 上皮钙黏蛋白 预后 Epithelial ovarian cancer Yes associated protein 1 Epithelial cadherin Prognosis
  • 相关文献

参考文献11

二级参考文献73

  • 1Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem[J]. Best Pract Res Clin Obstet Gynaecol,2006,20 ( 2 ) : 207-225.
  • 2Badgwell D, Bast RC Jr. Early detection of ovarian cancer [ J ]. Dis Markers, 2007,23(5-6) :397-410.
  • 3Cragun JM. Screening for ovarian cancer [ J ]. Cancer Control, 2011,18( 1 ) :16-21.
  • 4Myers ER,. Bastian LA, Havrilesky LJ. Management of adnexal mass[ J ]. Evid Rep Technol Assess ( Full Rep),2006, (130) : 1-145.
  • 5Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory [ J ]. Ann Clin Biochem,2011,48 ( Pt 4) :295-299.
  • 6Sjsvall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases[J]. Gynecol Oncol,2002,85( 1 ) :175-178.
  • 7Skates SJ, Horick N, Yu Y. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions [ J ]. J Clin Oncol, 2004,22(20):4059-4066.
  • 8Dorigo O, Berek JS. Personalizing CA125 levels for ovarian cancer screening[J]. Cancer Prev Res (Phila), 2011,4 ( 9 ) : 1356- 1359.
  • 9Xu Y, Gaudette DC, Boynton JD. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients [ J]. Clin Cancer Res, 1995, 1 (10) : 1223-1232.
  • 10Xu Y, Shen Z, Wiper DW. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers[J]. JAMA, 1998,280(8 ) :719-723.

共引文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部